INTRODUCTION {#sec1-1}
============

Thrombocytopenia, i.e., platelet count of \<150,000/µl is a rare side effect of psychotropic medications.\[[@ref1]\] However, in terms of clinical significance, a platelet count of \<50,000/µl is considered to be thrombocytopenia which requires emergency treatment.\[[@ref2]\] Thrombocytopenia is a rarely reported side effect of antipsychotic medications. Among the typical antipsychotic medications, the incidence of thrombocytopenia has been reported to be more with phenothiazines when compared to haloperidol.\[[@ref3]\] Among the atypical antipsychotics, it is more often reported with clozapine,\[[@ref4][@ref5][@ref6]\] although there are few case reports pointing to the association of olanzapine,\[[@ref7][@ref8][@ref9][@ref10]\] risperidone,\[[@ref11][@ref12]\] and quetiapine\[[@ref13][@ref14][@ref15]\] with thrombocytopenia.

In view of limited literature on the association of olanzapine and thrombocytopenia, we present a case of olanzapine-induced thrombocytopenia and review the existing literature.

CASE REPORT {#sec1-2}
===========

Miss. A, a 32-year-old, graduate, hailing from an urban background, with no family history of mental illness, presented with an insidious onset of continuous psychotic illness of 12 years duration. The illness was characterized by well-formed and systematized delusion of love involving one of her male colleagues. Initially, the delusional beliefs were limited to love only, but later, these extended to being persecutory delusions too. These symptoms led to marked socio-occupational dysfunction as the patient did not take up any job despite having multiple job offers and became homebound. She was treated with adequate doses of amisulpiride and trifluperazine for an adequate duration (each trial lasting for at least 3 months) with no improvement.

At the time of initial assessment, her physical examination did not reveal any abnormality and her mental status examination revealed delusion of persecution. Based on the history, a diagnosis of persistent delusional disorder (as per the International Classification of Diseases, Revision 10) was considered. Routine investigations including hemogram did not reveal abnormality at the initial evaluation and her platelet count was 3.5 lakhs/mm^3^. She was started on tablet olanzapine which was gradually increased to 25 mg/day over 6 weeks, with no significant improvement. Following this, it was planned to start clozapine, and during the preclozapine evaluation (during the 7^th^ week of olanzapine therapy), she was found to have an evidence of low platelet count (46,000/mm^3^) without any clinical manifestations of thrombocytopenia. There was no reduction in the blood cells of other lines. She was thoroughly evaluated for thrombocytopenia. There was no history of any fever, signs and symptoms suggestive of any local or systemic infection and intake of any other medications. Physical examination did not reveal any evidence of hepato-splenomegaly. Blood film did not reveal any evidence of dysplastic cells, disturbance in the count of other cell lines, and autoimmune workup including antinuclear antibodies and anti-neutrophil cytoplasmic antibodies were found to be negative. Over the next 2 months, multiple hemograms showed platelet counts to vary from 40,000 to 70,000/µl with no abnormalities in the other cell counts and clinical manifestations of thrombocytopenia. Given persistent thrombocytopenia and persistent psychopathology, the patient was admitted for a detailed evaluation. Olanzapine was gradually tapered off along with monitoring of platelet count. Serial monitoring revealed an increase in the total platelet count while olanzapine was being tapered and platelet count reached to the normal range (160,000/µl) after complete stoppage of olanzapine. Following this, a possibility of olanzapine-induced thrombocytopenia was considered. Later on, clozapine was started which was gradually increased to 200 mg/day with biweekly monitoring of the total platelet count before each increment in the dose of clozapine. No decline in platelet count was noted while the patient was on clozapine. With clozapine, her psychotic symptoms improved by 60%. Over the next 6-month follow-up period, her platelet counts remained within normal limit while on clozapine.

DISCUSSION {#sec1-3}
==========

In the index case, olanzapine-associated thrombocytopenia was detected accidentally. In fact, it was never considered, despite the presence of low platelet count for 3 months.

Thrombocytopenia has rarely been reported to be associated with the use of olanzapine, and there are no exact data on the incidence of thrombocytopenia with the use of olanzapine. In PubMed search, we could find only eight published case reports on the association of thrombocytopenia with olanzapine. As shown in [Table 1](#T1){ref-type="table"}, in many of these reports (five case reports), thrombocytopenia was associated with disturbances in the blood cells of other lines too.\[[@ref10][@ref16][@ref17][@ref18][@ref19]\] Further, in one of the cases, thrombocytopenia could be attributed to folate deficiency.\[[@ref10]\] Some of these reports also suggest that patients who experienced thrombocytopenia with olanzapine also experienced the same with the use of other medications such as benztropinemesylate\[[@ref8]\] and neutropenia with clozapine.\[[@ref19][@ref20]\] In contrast to these reports, the index case tolerated clozapine without any complications. One of the previous case reports also suggests that sequential use of olanzapine and clozapine does not suggest that if a patient develops thrombocytopenia with one drug, the patient is definitely going to develop thrombocytopenia with the second drug.\[[@ref17]\] Our case also supports this assertion. In the index case, the Naranjo probability score\[[@ref21]\] was 9 indicating a definite association of thrombocytopenia with olanzapine in the index case.

###### 

Olanzapine-induced thrombocytopenia along with other associated blood cells abnormalities
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Our case adds to the limited existing literature of olanzapine-induced thrombocytopenia and suggests that whenever a patient receiving olanzapine has an objective evidence of thrombocytopenia, olanzapine must be suspected as a cause and clinical evaluation must include the stoppage of medication as one of the strategies for the evaluation of thrombocytopenia.
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